Publications Noordermeer Lab
2024
Finding novel vulnerabilities of hypomorphic BRCA1 alleles.
BioRXiV
Schreuder A, De Lint K, Góis MM, Kampen RA, San Martin Alonso M, Nootenboom I, Garzero V, Wolthuis RMF, Noordermeer SM.
Mechanism of BRCA1-BARD1 function in DNA end resection and DNA protection.
Nature, 2024:634(8033)
Ceppi I, Dello Stritto MR, Mütze M, Braunshier S, Mengoli V, Reginato G, Võ HMP, Jimeno S, Acharya A, Roy M, Sanchez A, Halder S, Howard SM, Guérois, Huertas P, Noordermeer SM, Seidel R, Cejka P.
Chemo-Phosphoproteomic Profiling with ATR Inhibitors Berzosertib and Gartisertib Uncovers New Biomarkers and DNA Damage Response Regulators.
Molecular and Cellular Proteomics, 2024;23(8)
Jadav R, Weiland F, Noordermeer SM, Carroll T, Gao Y, Wang J, Zhou H, Lamoliatte F, Toth R, Macartney T, Brown F, Hastie CJ, Alabert C, Van Attikum H, Zenke F, Masson JY, Rouse J.
(single-stranded DNA) gaps in understandings BRCAness.
Trends in Genetics, 2024:40(9)
Schreuder A, Wendel TJ, Dorresteijn CGV, Noordermeer SM.
EXO1 protects BRCA1-deficient cells against toxic DNA lesions.
Molecular Cell, 2024 Feb;84(4)
Van de Kooij B, Schreuder A, Pavani RS, Garzero V, Uruci S, Wendel TJ, Van Hoeck A, San Martin Alonso M, Everts M, Koerse D, Callen E, Boom J, Mei H, Cuppen E, Luijsterburg MS, Van Vugt MATM, Nussenzweig A, Van Attikum H, Noordermeer SM.
2022
Editorial: Protecting the code: DNA double-strand break repair pathway choice.
Frontiers in Genetics., 2022 Aug;13
Singh J, Noordermeer SM, Jimenez-Sainz, Maranon DG, Altmeyer M.
2021
Two redundant ubiquitin-dependent pathways of BRCA1 localization to DNA damage sites.
EMBO reports, 2021 Dec;22(12)
Sherker A, Chaudhary N, Adam S, Heijnk AM, Noordermeer SM, Fradet-Turcotte A, Durocher D.
The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer.
Nature Cancer, 2021 Nov;2
Adam S, Rossi SE, Moatti N, De Marco Zompit M, Xue Y, Ng TF, Álvarez-Quilón A, Desjardins J, Bhaskaran V, Martino G, Setiaputra D, Noordermeer SM, Ohsumi TK, Hustedt N, Szilard RK, Chaudhary N, Munro M, Veloso A, Melo H, Yin SY, Papp R, Young JTF, Zinda M, Stucki M, Durocher D
ELOF1 is a transcription-coupled DNA repair factor that directs RNA polymerase II ubiquitylation.
Nature Cell Biology, 2021 Jun;23(6)
Van der Weegen Y, De Lint K, Van den Heuvel D, Nakazawa Y, Mevissen TET, Van Schie JJM, San Martin Alonso M, Boer D, González-Prieto R, Venkata Narayanan I, Klaassen NHM, Wondergem AP, Roohollahi K, Dorsman J, Hara Y, Vertegaal ACO, De Lange J, Walter JC, Noordermeer SM, Ljungman M, Ogi T, Wolthuis RMF, Luijsterburg SM.
Untangling the crosstalk between BRCA1 and R-loops during DNA repair.
Nucleic Acids Research, 2021 May;49(9)
San Martin Alonso M and Noordermeer SM.
2019
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
Trends in Cell Biology, 2019 Oct;29(10)
Noordermeer SM and Van Attikum H.
2018
The Shieldin complex mediates 53BP1-dependent DNA repair.
Nature, 2018 Aug; 560(7716)
Noordermeer SM*, Adam S*, Setiaputra D*, Barazas M, Pettitt SJ, Ling AK, Olivieri M, Álvarez-Quilón A, Moatti N, Zimmermann M, Annunziato S, Krastev DB, Song F, Brandsma I, Frankum J, Brough R, Sherker A, Landry S, Szilard RK, Munro MM, McEwan A, Goullet de Rugy T, Lin ZY, Hart T, Moffat J, Gingras AC, Martin A, Van Attikum H, Jonkers J, Lord CJ, Rottenberg S, Durocher D.
Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency.
Nature Biotechnology, 2018 Jan; 36(1)
Canny M, Moatti N, Wang L, Fradet-Turcotte A, Krasner D, Mateos-Gomez P, Zimmermann M, Orthwein A, Juang Y, Zhang W, Noordermeer SM, Seclen E, Wilson M, Vorobyov A, Munro M, Ernst A, Ng T, Cho T, Cannon P, Sidhu S, Sicheri F, Durocher D.
2017
ATM and Cdk2 control chromatin remodeler CSB to establish feedback inhibition of RIF1 in DNA DSB repair pathway choice.
Nature Communications, 2017 Dec; 8(1)
Batenburg NL, Walker JR, Noordermeer SM, Moatti N, Durocher D, Zhu XD.
2016
The structural basis of modified nucleosome recognition by 53BP1.
Nature, 2016 Aug; 536(7614)
Wilson MD, Benlekbir S, Fradet-Turcotte A, Sherker A, Julien JP, McEwan A, Noordermeer SM, Sicheri F, Rubinstein JL, Durocher D.
2014
High DNA-methyltransferase 3B expression predicts poor outcome in acute myeloid leukemia, especially among patients with co-occurring NPM1 and FLT3 mutations.
Blood Cancer J., 2014 Aug; 4:e233
Monteferrario D*, Noordermeer SM*, Bergevoet SM, Huls G, Jansen JH, Van der Reijden BA.
2013
53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark.
Nature, 2013 Jul; 499(7456).
Fradet-Turcotte A, Canny MD, Escribano-Díaz C, Orthwein A, Leung CC, Huang H, Landry MC, Kitevski-LeBlanc J, Noordermeer SM, Sicheri F, Durocher D.
2011
High BRE expression predicts favorable outcome in adult acute myeloid leukemia, in particular among MLL-AF9 positive patients.
Blood, 2011 Nov;118(20)
Noordermeer SM, Sanders MA, Gilissen C, Tönnissen E, Van der Heijden A, Döhner K, Bullinger L, Jansen JH, Valk PJM, Van der Reijden BA.
Rapid identification of IDH1 and IDH2 mutations in acute myeloid leukaemia using high resolution melting curve analysis.
Br J Haematol, 2011 Feb;152(4)
Noordermeer SM, Tönnissen E, Vissers I, Van Der Heijden A, Van De Locht LT, Deutz-Terlouw PP, Marijt EW, Jansen JH, Van Der Reijden BA.
2009
The ubiquitin ligase Triad1 inhibits myelopoiesis through UbcH7 and Ubc13 interacting domains.
Leukemia, 2009 Aug;23(8)
Marteijn JA, van der Meer LT, Smit JJ, Noordermeer SM, Wissink W, Jansen P, Swarts HG, Hibbert RG, de Witte T, Sixma TK, Jansen JH, Van der Reijden BA.